Sangamo is conducting several clinical trials to evaluate the safety, tolerability, and potential efficacy of its genomic medicines, some of which we lead and some of which are led by our global pharmaceutical company collaboration partners.
Sangamo’s novel technology and depth of scientific expertise make us a partner of choice among leading global pharmaceutical companies. Whether through in-licensing, out-licensing, scientific collaborations or advancing our corporate development priorities, our collaborations extend the reach of our technology and accelerate the development of genomic medicines. These are some of the ways we deliver on our commitment to get new treatments to patients in need.
Chroma Medicine has a research evaluation, option and license agreement with Sangamo to explore zinc finger proteins (ZFPs) for epigenetic editing in specified targets outside of the central nervous system.
Kite, a Gilead Company, and Sangamo are developing next-generation ex vivo cell therapies to treat cancer by using Sangamo’s zinc finger nuclease (ZFN) technology.
Pfizer and Sangamo have an exclusive, global collaboration and license agreement to develop and commercialize gene therapies for hemophilia. Sangamo and Pfizer are also collaborating for the development and commercialization of therapeutics using our zinc finger protein transcription factors (ZFP-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.
Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, has a research evaluation and option agreement with Sangamo to evaluate certain proprietary novel engineered cerebrospinal fluid-administered capsids with enhanced nervous system delivery, generated through Sangamo’s capsid engineering platform, SIFTER.
Takeda and Sangamo are developing therapeutics for Huntington's disease utilizing our ZFP-TF genome regulation platform.
Sangamo has entered into an agreement with Voyager Therapeutics to license Voyager’s intravenous-administered delivery capsid, which has been shown in animal models to achieve the specific central nervous system coverage we believe to be required for Sangamo’s epigenetic regulation program for prion disease.
Contact Mark McClung, Executive Vice President, Chief Operating Officer